GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Adalta 1AD.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.00

-33.33%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Adalta — daily ASX:1AD

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Adalta on TradingView ↗
Market value
A$1.6m
Last close × shares
Volume
2.8m
Shares, 9 Nov 2026

About Adalta

Its shares trade on ASX under the ticker 1AD.AX. It has been listed since 22 August 2016. In the fiscal year to 30 June 2025, it reported revenue of A$677,010 and a net loss of A$4.5m. At that date it held total assets of A$2.1m and shareholders' equity of −A$598,244.

AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies.

Figures and description from our data supplier, not checked against the company's own report.

More about Adalta →

Latest on Adalta

Our reporting

We have not reported on Adalta yet.

Next results

25 Feb 2027

Due on 25 Feb 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Adalta's ticker?

Adalta trades as 1AD.AX on ASX, under ISIN AU0000001AD2.

What was Adalta's last closing price?

0.00 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Adalta next report results?

Results are expected on 25 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.